AbbVie Inc. Non-current Liabilities (Other)

Non-current Liabilities (Other) of ABBV for past 10 years: annual, quarterly and twelve month trailing (TTM) including Non-current Liabilities (Other) growth rates and interactive chart.


Highlights and Quick Summary

  • Non-current Liabilities (Other) for the quarter ending September 29, 2019 was $16 Billion (a -0.06% decrease compared to previous quarter)
  • Year-over-year quarterly Non-current Liabilities (Other) increased by 10.35%
  • Annual Non-current Liabilities (Other) for 2018 was $14.5 Billion (a -7.15% decrease from previous year)
  • Annual Non-current Liabilities (Other) for 2017 was $15.6 Billion (a 86.84% increase from previous year)
  • Annual Non-current Liabilities (Other) for 2016 was $8.35 Billion (a 126.04% increase from previous year)
Visit stockrow.com/ABBV for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Non-current Liabilities (Other) of AbbVie Inc.

Most recent Non-current Liabilities (Other)of ABBV including historical data for past 10 years.

Interactive Chart of Non-current Liabilities (Other) of AbbVie Inc.

AbbVie Inc. Non-current Liabilities (Other) for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2019 $15,990.0 $16,000.0 $14,509.0
2018 $14,490.0 $15,721.0 $15,543.0 $15,521.0 $14,490.0
2017 $15,605.0 $8,999.0 $8,518.0 $8,499.0 $15,605.0
2016 $8,352.0 $7,646.0 $7,791.0 $3,513.0 $8,352.0
2015 $3,695.0 $3,801.0 $3,918.0 $3,589.0 $3,695.0
2014 $3,681.0 $2,705.0 $3,040.0 $3,358.0 $3,681.0
2013 $3,535.0 $3,425.0 $3,221.0 $2,845.0 $3,535.0
2012 $2,239.0 $1,693.25 $1,364.76 $1,395.84 $2,239.0
2011 $1,660.0 $1,660.0
2010 $1,670.45 $1,670.46

Business Profile of AbbVie Inc.

Sector: Medical
Industry: Drugs
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products in the United States, Japan, Germany, Canada, Italy, Spain, the Netherlands, the United Kingdom, Brazil, and internationally. It offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behcet's diseases; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenstrom's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C virus (HCV); TECHNIVIE to treat adults with genotype 4 HCV infection; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides KALETRA, an anti-human immunodeficiency virus (HIV)-1 medicine used with other anti-HIV-1 medications to maintain viral suppression in HIV-1 patients; NORVIR, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1; and SYNAGIS to prevent respiratory syncytial virus infection at-risk infants. In addition, it offers AndroGel, a testosterone replacement therapy; CREON, a pancreatic enzyme therapy; Synthroid to treat hypothyroidism; and Lupron to treat prostate cancer, endometriosis, and central precocious puberty, as well as anemia. Further, it provides Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Sevoflurane, an anesthesia product; and ORILISSA, a non-peptide molecule gonadotropin-releasing hormone antagonist. It has collaborations with Alector, Inc.; Janssen Biotech, Inc.; Galapagos; Bristol-Myers Squibb Company; Calico Life Sciences LLC; Cystic Fibrosis Foundation; Dragonfly Therapeutics, Inc.; and Pan-Canadian Pharmaceutical Alliance. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.